Biotech 12 Pack Watch List to be Released.
In 2020, we Released the “Biotech 5 Pack” Which Later Grew to a 6 Pack, with a Byline “6 Stocks We Expect to Double” and Second Byline of “Potential to at Least Double.”
Drum roll.. four of the six doubled. Not bad.
Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.
ABVC Pharma gained 200%
Citius gained 261%
Dicerna gained 88%
Dyadic gained 74%
Fortress Bio gained 103%
Immunomedics gained 383%
Note the initiation price when we first initiated coverage. As example we added Immunomedics to Watch List at $3.00 and then we next added it to the Stocks we expect to double list, when it had already gone up to $18 (a bold, or some might call it foolish expectation) – so the full gain from initiation of coverage was 2,800%, when it was acquired at $87. Similar to Dicerna which went from $3.30 to $20, then added to 5 Pack, after which it was acquired at $38.
Note for legal reasons we use the term ‘expect,’ as in if everything pans out like we think (hope) it will. Expect does not mean project, predict or target. If they fail to reach our expectations, we won’t say we failed, we’ll simply say the company failed, to reach our expectations. Happens all the time.
We waited this long (nearly 5 months into 2026) because our technical analyst was expecting a major draw down last January amongst Biotech’s, similar to the draw down in late 2024 – when they dropped by nearly a third. Being in Biotech’s for nearly 30 years, we’re not scared of volatility, but it’s nice when you can pick up some market related bargains by being patient.
BIOTECH 12 PACK WATCH LIST OF STOCKS WE EXPECT TO DOUBLE
So here are the first four. We’d put the names into a nice chart like above but happy hour is upon us, and a man must have priorities. Just saying.
Cabaletta (CABA) $3.07, up 140% in past year.
GeoVax (GOVX) $1.14, down 73% year to date.
PolyPid (PYPD) $4.68, up 72% in past year.
Replimune (REPL) $2.17, down 71% year to date.
There is a little something for everyone. From bargain hunters, to investors who don’t mind chasing something already nearing a double!
Here’s the game plan. We will issue a full report on GeoVax (GOVX) next, then issue stand alone reports on the rest, about once a week. The first writeup was on Replimune (REPL) because of a ‘special event,’ let’s call it.
Replimune REPL). $269 Million in Cash and a $178 Million Market Cap.
We will release the other 8 names within a week. And then continue reporting on the whole group as news is released.
MID AND LONG TERM CHARTS
CABALETTA (CABA)
GEOVAX (GOVX)
POLYPID LTD. (PYPD)
DISCLAIMER
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumors. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the our clinical trials and other updates, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. GeoVax is a client of Institutional Analyst (and not Katogen), the publisher of the Biotech Stock Review and has been retained with a combination of cash and equity for ongoing progress, news coverge and research reporting for five thousand dollars per month.
#GOVX, #REPL, #CABA, #PYPD
